An algorithm for medical management in male lower urinary tract symptoms

Current Opinion in Urology

Volumn 21, Issue 1, 2011, Pages 5-12

  Djavan, Bob ^a   Margreiter, Markus ^a   Dianat, Seyed Saeid ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

benign prostatic hyperplasia; combination drug therapy; lower urinary tract symptoms; monotherapy; treatment outcome

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; ELOCALCITOL; FINASTERIDE; GISADENAFIL; GROWTH HORMONE ANTIBODY; MUSCARINIC RECEPTOR BLOCKING AGENT; NAFTOPIDIL; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; SILODOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TADALAFIL; TAMSULOSIN; TERAZOSIN; TOLTERODINE;

ALGORITHM; ARTICLE; CONTROLLED DRUG RELEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; HEALTH CARE COST; HUMAN; LOWER URINARY TRACT SYMPTOM; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RETROGRADE EJACULATION; RISK REDUCTION; UNSPECIFIED SIDE EFFECT;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-ANTAGONISTS; ALGORITHMS; DRUG THERAPY, COMBINATION; HUMANS; MALE; MUSCARINIC ANTAGONISTS; PROSTATIC HYPERPLASIA; UROLOGIC DISEASES;

EID: 78650511663     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32834100ef     Document Type: Article

References (39)

1. Gravas S, Melekos MD.Male lower urinary tract symptoms: How do symptoms guide our choice of treatment? Curr Opin Urol 2009; 19:49-54.
2. Barkin J, Roehrborn CG, Siami P, et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int 2009; 103:919-926. This article shows the patient-reported QoL and treatment satisfaction of combination therapy compared with monotherapy as 2-year result of CombAT study.
3. Naslund M, Eaddy MT, Hogue SL, et al. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: Assessment of acute urinary retention and prostate-related surgery. Curr Med Res Opin 2009; 25:2663-2669.
4. Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57:123-131. This is the most updated report of CombAT study. Herein, the long-term consequences of combination therapy has been described. Symptom improvement, reduction in relative risk for acute urinary retention, BPH-related surgery, and BPH clinical progression over 4 years have been compared in different treatment arms.
5. Cantrell MA, Bream-Rouwenhorst HR, Hemerson P, Magera JS Jr. Silodosin for benign prostatic hyperplasia. Ann Pharmacother 2010; 44:302-310. A comprehensive review on pharmacological aspects of silodosin. This review also highlights the clinical trials on the efficacy and adverse effects of silodosin for treatment of LUTS.
6. Garimella PS, Fink HA, Macdonald R, Wilt TJ. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. Cochrane Database Syst Rev 2009; 4:CD007360. A systematic review on the efficacy of naftopidil for the treatment of LUTS in patients with BPH. There is no place-controlled study; however, short-term improvement in urinary symptoms and QoL score were detected which were comparable to low-dose tamsulosin administration. Few but mild adverse effects were also reported.
7. Kawabe K, Yoshida M, Homma Y. Silodosin, a new alpha1A- adrenoceptorselective antagonist for treating benign prostatic hyperplasia: Results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006; 98:1019-1024.
8. Marks LS, Gittelman MC, Hill LA, et al. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: Pooled results of 2 phase 3 studies. J Urol 2009; 181:2634-2640.
9. Homma Y, Kawabe K, Takeda M, Yoshida M. Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia. Urology 2010; (in press).
10. Yamanishi T, Mizuno T, Tatsumiya K, et al. Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia. Neurourol Urodyn 2010; 29:558-562. This is a study evaluating the urodynamic effects of silodosin, a new selective a1Areceptor blocker, for LUTS. It has been suggested that silodosin can improve detrusor overactivity and obstruction grade in patients with LUTS.
11. Wang C. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr Opin Urol 2010; 20:49-54. A review on the role of PDE5 inhibitors in BPH treatment either as monotherapy or combination therapy.
12. Porst H, McVary KT, Montorsi F, et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol 2009; 56:727-735. Post hoc analysis of a phase 2-3 study of men with erectile dysfunction and moderate-to-severe LUTS secondary to BPH. The effect of Tadalafil on erectile function, peak urinary flow rate, and LUTS has been reported.
13. Dmochowski R, Roehrborn C, Klise S, et al. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: A randomized, placebo controlled 12-week clinical trial. J Urol 2010; 183:1092-1097. This study evaluates the urodynamic changes in men treated with tadalafil and improvement in LUTS as measured with IPSS.
14. Broderick GA, Brock GB, Roehrborn CG, et al. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology 2010; 75:1452-1458. This study assessed the safety and efficacy of tadalafil for the treatment of LUTS in men with or without erectile dysfunction. This study suugests the possible role of tadalafil for treatment of both LUTS and erectile dysfunction especially in aging men.
15. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006; 50:1306-1314; discussion 1314-1305.
16. Abdel-Aziz KF, Lemack GE. Overactive bladder in the male patient: Bladder, outlet, or both? Curr Urol Rep 2002; 3:445-451.
17. Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: A randomized controlled trial. JAMA 2006; 296:2319-2328.
18. Roehrborn CG, Kaplan SA, Jones JS, et al. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: Effects of prostate size. Eur Urol 2009; 55:472-479.
19. Chapple C, Herschorn S, Abrams P, et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 2009; 56:534-541. Study on the efficacy of tolterodine extended release in patients with persistent LUTS after continued use of a-blockers. Bothersome OAB symptoms despite of a-blockers might be treated with tolterodine extended release for 12 weeks with continued a-blocker therapy.
20. Chung DE, Te AE, Staskin DR, Kaplan SA. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams. Urology 2010; 75:1144-1148. This study shows the efficay and safety of combination of tolterodine extended release and dutasteride in patients with persistent OAB symptoms and enlarge prostate despite of treatment with dutasteride alone.
21. Hofner K, Burkart M, Jacob G, Jonas U. Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed nonobstructive benign prostatic hyperplasia. World J Urol 2010; 28:353-357. This is a prospective, noninterventional observational study on the efficacy of tolterodine extended release in a subgroup of patients with OAB symptoms and presumbed nonobstructive BPH. In this study, the role of tolterodine extended release in this group of patients for the improvement of symptoms and QoL has been highlighted regardless of IPSS severity class, age, concomitant diabetes or a-blockers.
22. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387-2398.
23. Hollingsworth JM, Wei JT. Does the combination of an alpha1-adrenergic antagonist with a 5alpha-reductase inhibitor improve urinary symptoms more than either monotherapy? Curr Opin Urol 2010; 20:1-6. This is a systematic review of four trials comparing combination therapy of ablockers and 5a-reductase inhibitors with either monotherapy.
24. Becher E, Roehrborn CG, Siami P, et al. The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study. Prostate Cancer Prostatic Dis 2009; 12:369-374. This is the 2-year results of CombAT study. It has been shown that dutasteride may result in greater long-term control of not only overall urinary symptoms but also specific aspects of LUTS in men with enlarged prostate than tamsulosin. Dutasteride is as effective as tamsulosin for control of storage symptoms but provides a greater relief from voiding symptoms by 24 months of treatment.
25. Montorsi F, Henkel T, Geboers A, et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study. Int J Clin Pract 2010; 64:1042-1051. This study is the 4-year report of CombAT study. Patient-reported QoL and treatment satisfaction have been investigated in the combination and monotherapy arms. It has been shown that the significant superiority of combination therapy over both monotherapies reported on 2-year data is sustained out to 4 years.
26. Jeong YB, Kwon KS, Kim SD, Kim HJ. Effect of discontinuation of 5alphareductase inhibitors on prostate volume and symptoms in men with BPH: A prospective study. Urology 2009; 73:802-806.
27. Fenter TC, Davis EA, Shah MB, Lin PJ. Dutasteride vs finasteride: Assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged-65 years. Am J Manag Care 2008; 14:S154-S159.
28. Fenter TC, Runken MC, Black L, Eaddy M. Finasteride versus dutasteride: A real-world economic evaluation. Am J Manag Care 2007; 13 (Suppl 1):S23-S28.
29. Naslund M, Black L, Eaddy M, Batiste LR. Differences in alpha blocker usage among enlarged prostate patients receiving combination therapy with 5 ARIs. Am J Manag Care 2007; 13 (Suppl 1):S17-S22.
30. The first fixed dose combination medicine for benign prostatic hyperplasia. http://www.gsk.com/media/pressreleases/2010/2010-pressrelease- 10036.htm.[Accessed 10 August 2010]
31. FDA approves JalynTM, a fixed-dose combination of dutasteride and tamsulosin, for symptomatic BPH in men with an enlarged prostate. http://us.gsk. com/html/media-news/pressreleases/2010/2010-us-pressrelease-10035. htm. [Accessed 28 July 2010]
32. Oelke M, Bachmann A, Descazeaud A, et al. Guidelines on conservative treatment of nonneurogenic male LUTS. http://www.uroweb.org/?id=218&gid=7. [Accessed 29 July 2010]
33. Tuncel A, Nalcacioglu V, Ener K, et al. Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol 2010; 28:17-22.
34. Roehrborn CG. Clinical management of lower urinary tract symptoms with combined medical therapy. BJU Int 2008; 102 (Suppl 2):13-17.
35. Cornu JN, Cussenot O, Haab F, Lukacs B. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur Urol 2010; 58:450-456. This study compares the actual clinical practice for BPH management across European countries with EAU guidelines. This widespread population study helps to know about the actual management of LUTS across Europe.
36. Emberton M. Medical treatment of benign prostatic hyperplasia: Physician and patient preferences and satisfaction. Int J Clin Pract 2010; 64:1425-1435. A systematic review evaluating the patients' and physicians' preferred treatment options for managing BPH and patient satisfaction with therapy.
37. Adorini L, Penna G, Fibbi B, Maggi M. Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia. Ann N Y Acad Sci 2010; 1193:146-152.
38. Siejka A, Schally AV, Block NL, Barabutis N. Antagonists of growth hormonereleasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells. Prostate 2010; 70:1087-1093.
39. Tamimi NA, Mincik I, Haughie S, et al. A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. BJU Int 2010; 106: 674-680